Trial reportClinical pharmacology in drug development2021
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Trial report in Clinical pharmacology in drug development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study.Lupus science & medicine · 2025Trial
- Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.Clinical pharmacology and therapeutics · 2022Trial
- Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.Clinical pharmacology in drug development · 2021Trial
- Clinical Management of Antirheumatic Drug Exposure During Therapeutic Plasma Exchange.Clinical reviews in allergy & immunology · 2026Review
- Population pharmacokinetics of tofacitinib in patients with active ankylosing spondylitis.International journal of clinical pharmacology and therapeutics · 2026Article
- Sex-Specific Real-Life Profiling in Vedolizumab, Ustekinumab, and Tofacitinib Effectiveness in Ulcerative Colitis.Journal of clinical medicine · 2025Article
- Therapeutic Drug Monitoring for Precision Dosing of Janus Kinase Inhibitors: Protocol for a Prospective Observational Study.JMIR research protocols · 2025Article
- A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel disease.United European gastroenterology journal · 2024Review
- Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis.CPT: pharmacometrics & systems pharmacology · 2024Article
- Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Bridging Efficacy of Tofacitinib Immediate-Release to Extended-Release Formulations for Treatment of Ulcerative Colitis: Application of a Model-Informed Drug Development Approach.Clinical pharmacology in drug development · 2022Article
- Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis.Nagoya journal of medical science · 2022Article
- Small Molecule Drugs in Inflammatory Bowel Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We characterized tofacitinib pharmacokinetics in patients with moderate to severe UC, and the effects of covariates on variability in pharmacokinetic parameter estimates. Data were pooled from 1 8-week phase 2 and 2 8-week phase 3 induction studies, and a 52-week phase 3 maintenance study (N = 1096). Population pharmacokinetic analysis was conducted using nonlinear mixed-effects modeling. Potential predictors of apparent oral clearance (CL/F) and volume of distribution (V/F) were evaluated. The PK was described by a 1-compartment model parameterized in terms of CL/F (26.3 L/hour [h]) and V/F (115.8 L), with first-order absorption (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.